Mesa Laboratories, Inc. MLAB
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +69.95%
- 1 year
- +88.65%
- Market cap
- 749.83M
- Revenue (ttm)
- 228.38M
- Profit margin
- -107.56%
- EPS (ttm)
- 1.12
- Shares out
- 5.43M
- P/E ratio
- 119.12
- Forward P/E
- 18.42
- Dividend
- 0.64 (0.48%)
- Ex-dividend date
- Nov 29, 2024
- YTD return
- +69.95%
- 1-year return
- +88.65%
- Volume
- 101.74K
- Avg volume
- 117.63K
- Open
- 140.29
- Previous close
- 137.81
- Day's range
- 132.99 – 140.29
- 52-week range
- 70.19 – 144.35
- Beta
- 0.86
- Price target
- 133.33 (-0.1%)
- 50-day average
- 120.63
- 200-day average
- 113.75
- Enterprise value
- 914.23M
Key statistics
- Price / sales
- 3.22
- Price / book
- 4.55
- Payout ratio
- 376.47%
- Revenue growth
- 8.80%
- Free cash flow
- 48.73M
- Total cash
- 26.00M
- Total debt
- 222.86M
- Return on equity
- -89.46%
- Short % of float
- 3.97%
Fundamental scorecard
15 of 25 checks passed on MLAB’s reported financials
15of 25 checks passed
- Value 2 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 2 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2025 | Dec 1, 2024 | 2.45 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | 2.48 | 2.45 | -0.03 | -1.21% |
| Aug 5, 2024 | Jun 1, 2024 | 2.33 | 2.83 | +0.50 | +21.46% |
| Feb 5, 2024 | Dec 1, 2023 | 2.04 | 2.02 | -0.02 | -0.98% |
| Nov 6, 2023 | Sep 1, 2023 | 1.65 | 1.91 | +0.26 | +15.76% |
| Aug 3, 2023 | Jun 1, 2023 | 1.67 | 1.77 | +0.10 | +5.99% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Aug 27, 2024 | Wells Fargo | init | — | Underweight |
| Aug 6, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Jul 2, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Apr 4, 2024 | Evercore ISI Group | main | Outperform | Outperform |
| Jan 4, 2024 | Evercore ISI Group | up | In-Line | Outperform |
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
- Sector
- Technology
- Industry
- Scientific & Technical Instruments
- Country
- United States
- Website
- mesalabs.com
News
Jefferies Maintains Buy on Mesa Laboratories, Raises Price Target to $150
Mesa Laboratories, Inc. (MLAB) Q2 2027 Earnings Call Transcript
What Mesa Laboratories (MLAB) Said on Its Q2 Earnings Call Mesa Laboratories Sees FY2027 Sales $250.000M-$255.000M vs $254.450M Est
Mesa Laboratories Q2 2027 Earnings Call Transcript
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance
Mesa Labs Announces Second Quarter Financial Results Release Date and Earnings Conference Call
Diamond Hill Small Cap Fund Q3 2026 Portfolio Activity
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
Mesa Laboratories (NASDAQ:MLAB) Hits New 12-Month High – Should You Buy?
Your note
Sign in to keep a note on MLAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLTOFT JENNIFER SADIE | Director | Conversion of Exercise of derivative security | Aug 29, 2024 | 3,474 |
| ARCHBOLD BRIAN DAVID | Officer | Sale | Sep 12, 2024 | 0 |
| CAPONE MARK CHRISTOPHER | Director | Conversion of Exercise of derivative security | Aug 14, 2024 | 724 |
| HALL SHANNON | Director | Conversion of Exercise of derivative security | Aug 29, 2024 | 2,785 |
| LADIWALA SHIRAZ SHABANALI | Director | Conversion of Exercise of derivative security | Aug 29, 2024 | 3,074 |
| OWENS GARY M | Chief Executive Officer | Sale | Oct 28, 2024 | 43,337 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.41% | 836,821 | 113.31M | Sep 29, 2024 |
| Conestoga Capital Advisors, LLC | 9.74% | 529,110 | 71.64M | Sep 29, 2024 |
| Vanguard Group Inc | 6.95% | 377,582 | 51.12M | Sep 29, 2024 |
| Royce & Associates LP | 6.39% | 347,145 | 47.00M | Sep 29, 2024 |
| Morgan Stanley | 4.59% | 249,348 | 33.76M | Sep 29, 2024 |
| Ranger Investment Management, L.p. | 4.39% | 238,190 | 32.25M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Conestoga Small Cap Fund | 6.70% | 363,985 | 49.28M | Sep 29, 2024 |
| iShares Core S&P Smallcap ETF | 6.33% | 343,770 | 46.55M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.94% | 159,571 | 21.61M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.43% | 131,945 | 17.87M | Oct 30, 2024 |
| Royce Small-Cap Fund | 1.92% | 104,550 | 14.16M | Sep 29, 2024 |
| Royce Micro Cap Trust | 1.92% | 104,132 | 14.10M | Sep 29, 2024 |
